Presidential order could accelerate approval of psychedelics

A new executive order from the White House could jump‐start additional research and new approvals of psychedelic drugs for the treatment of serious mental illness (SMI). Among its provisions, the April 18 order directs federal agencies to expedite reviews of products that have successfully completed Phase 3 trials, so that they can be more rapidly rescheduled from their current Schedule I (no recognized medical use) status.